TABLE 1.
Meta-analysis Study Characteristics
| Study, y | Trial name | Phase (design) | EGFR inhibitor dosage | Treatment groupa |
|---|---|---|---|---|
| Zhong et al, 201819 | ADJUVANT/CTONG1104 | 3 (RCT) | Gefitinib 250 mg/d for 24 mo | EGFR inhibitors |
| Wu et al, 201820 | LUX LUNG 6 | 3 (RCT) | Afatinib 40 mg/d with increment of 10 mg/d if no adverse effects | EGFR inhibitors |
| Shi et al, 201721 | CONVINCE | 3 (RCT) | Icotinib 125 mg 3 times daily | EGFR inhibitors |
| Soria et al, 201522 | IMPRESS | 3 (RCT) | Gefitinib 250 mg/d for 24 mo | EGFR inhibitors |
| Goss et al, 201323 | NCIC CTG BR19 | 3 (RCT) | Gefitinib 250 mg/d for 24 mo | EGFR inhibitors |
| Mu Sun et al, 201224 | KCSG-LU08-01 | 3 (RCT) | Gefitinib 250 mg/d for 24 mo | EGFR inhibitors |
| Mitsudomi et al, 201125 | WJTOG3405 | 3 (RCT) | Gefitinib 250 mg/d | EGFR inhibitors |
| Lee et al, 201026 | ISTANA | 3 (RCT) | Gefitinib 250 mg/d | EGFR inhibitors |
| Kim et al, 200827 | INTEREST | 3 (RCT) | Gefitinib 250 mg/d | EGFR inhibitors |
Abbreviations: EGFR, epidermal growth factor receptor; RCT, randomized controlled trial.
a
All control groups treated with platinum-based chemotherapy.